US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Cardiovascular

20.00

0.0000

Volume:- -

Turnover:- -

Market Cap:843.96M

PE:-20.84

High:20.00

Open:20.00

Low:20.00

Close:20.00

52wk High:23.47

52wk Low:12.26

Shares:42.20M

Float Shares:40.69M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.9598

EPS(LYR):-0.9415

ROE:-15.18%

ROA:-7.56%

PB:3.53

PE(LYR):-21.24

Loading ...

Overview Company News Filings

This Medical Device Maker Is Seeing High Demand In Cardiovascular, Diabetes Business

Acotec Scientific Gains Approval for New Cardiovascular Device

Amgen (AMGN) Is Up 5.6% After Repatha Phase 3 Trial Shows Cardiovascular Benefits – Has The Bull Case Changed?

Simply Wall St.

CRISPR Therapeutics (CRSP): Assessing Valuation Following Promising Early CTX310 Cardiovascular Trial Results

Simply Wall St.

Amgen Says Repatha Significantly Reduces Risk of Cardiovascular Event in Phase 3 Study

MT Newswires Live

New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients

Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases

King-Friend Biochemical Pharmaceutical Passes Drug Consistency Evaluation for Cardiovascular Drug

MT Newswires Live

Higher-Dose Of Wegovy Demonstrates Weight Loss And Cardiovascular Benefits

Alnylam’s ZENITH Study: A New Horizon in Cardiovascular Treatment

Amgen’s Maridebart Cafraglutide: A New Hope for Cardiovascular Health?

NewAmsterdam Pharma’s REMBRANDT Trial: A Potential Game-Changer in Cardiovascular Treatment

Amarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit

Autonomix Medical, Inc. Featured in Two Innovation in Interventional Cardiology Podium Presentations at the Transcatheter Cardiovascular Therapeutics® (TCT®) Annual Scientific Conference

Semler Scientific’s QuantaFlo HD Study: A Potential Game-Changer in Cardiovascular Diagnostics

Boston Scientific Raises Outlook on Continued Cardiovascular Growth

Could Caristo Collaboration Reveal NewAmsterdam Pharma’s (NAMS) Real Edge in Cardiovascular Innovation?

Simply Wall St.

HLS Therapeutics and Amarin Highlight Cardiovascular Advances at Canadian Congress

Shandong Xinhua Pharmaceutical Gets Regulatory Nod for Cardiovascular Drug

MT Newswires Live

Strategic Shift Towards Cardiovascular Platform Positions Rocket Pharmaceuticals for Future Growth

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CSII/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CSII","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSII\",,,,,undefined,":{"symbol":"CSII","market":"US","secType":"STK","nameCN":"Cardiovascular","latestPrice":20,"timestamp":1688155200000,"preClose":20,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":40687277,"shares":42198048,"eps":-0.959831,"marketStatus":"Trading","change":0,"latestTime":"03-06 14:56:47 EST","open":20,"high":20,"low":20,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.959831,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1772830800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1151467200000,"exchange":"NASDAQ","adjPreClose":20,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSII\",,,,,undefined,":{"symbol":"CSII","floatShares":40687277,"roa":"-7.56%","roe":"-15.18%","lyrEps":-0.941454,"shares":42198048,"dividePrice":0,"high":20,"amplitude":0,"preClose":20,"low":20,"week52Low":12.255,"pbRate":"3.53","psRate":"3.52","week52High":23.47,"institutionHeld":0.4085,"latestPrice":20,"eps":-0.959831,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.959831,"open":20,"prevYearClose":13.62},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSII\",params:#limit:5,,,undefined,":[{"market":"US","date":"2023-04-28","symbol":"CSII","reason":null,"defaultRemindTime":1682688600000,"announcedDate":"2023-04-27","type":"delisting","dateTimestamp":1682654400000},{"date":"2023-02-09","symbol":"CSII","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2022/12","expectedEps":-0.15,"defaultRemindTime":1675933200000,"name":null,"time":"Pre-Market","dateTimestamp":1675918800000,"actualEps":null},{"market":"US","date":"2022-08-02","symbol":"CSII","fiscalQuarterEnding":"2022/06","expectedEps":-0.22,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1659412800000,"reportTimeType":"post","actualEps":-0.25},{"market":"US","date":"2022-05-04","symbol":"CSII","fiscalQuarterEnding":"2022/03","expectedEps":-0.28,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1651636800000,"reportTimeType":"pre","actualEps":-0.25},{"market":"US","date":"2021-11-09","symbol":"CSII","fiscalQuarterEnding":"2021/09","expectedEps":-0.1,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1636434000000,"reportTimeType":"pre","actualEps":-0.22}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSII\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CSII\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":0.6667,"sell":0.3333,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.6667,"analysts":6,"updateTime":1676001600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CSII\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CSII","date":"2023-04-26","current":-20.837002,"percent":0.602228,"low":-7142.134596,"twenty":-150.263532,"median":-47.492643,"eighty":648.895851,"high":1513.025574,"avg":-244.968737,"sd":1483.721277,"marketCap":843538979},"quantilePoints":[{"date":"2021-03-12","current":-83.461931,"twenty":-223.323098,"median":-21.854907,"eighty":649.309001,"marketCap":1684845999},{"date":"2021-03-19","current":-80.435639,"twenty":-223.323098,"median":-21.959778,"eighty":649.309001,"marketCap":1623754254},{"date":"2021-03-26","current":-77.787635,"twenty":-223.145513,"median":-22.077677,"eighty":649.10488,"marketCap":1570298978},{"date":"2021-04-01","current":-74.442786,"twenty":-223.145513,"median":-22.365875,"eighty":649.10488,"marketCap":1502776524},{"date":"2021-04-09","current":-71.93415,"twenty":-223.323098,"median":-22.46194,"eighty":649.309001,"marketCap":1452134683},{"date":"2021-04-16","current":-77.608446,"twenty":-223.323098,"median":-22.539344,"eighty":649.309001,"marketCap":1566681704},{"date":"2021-04-23","current":-81.072753,"twenty":-223.323098,"median":-22.783943,"eighty":649.309001,"marketCap":1636615674},{"date":"2021-04-30","current":-80.276361,"twenty":-223.145513,"median":-22.907337,"eighty":649.10488,"marketCap":1620538899},{"date":"2021-05-07","current":-61.125515,"twenty":-223.145513,"median":-23.047069,"eighty":649.10488,"marketCap":1424346748},{"date":"2021-05-14","current":-62.685323,"twenty":-223.145513,"median":-23.118044,"eighty":649.10488,"marketCap":1460693394},{"date":"2021-05-21","current":-66.40818,"twenty":-223.145513,"median":-23.448954,"eighty":649.10488,"marketCap":1547443401},{"date":"2021-05-28","current":-67.545719,"twenty":-223.145513,"median":-23.542167,"eighty":649.10488,"marketCap":1573950347},{"date":"2021-06-04","current":-65.701526,"twenty":-223.145513,"median":-23.665911,"eighty":649.10488,"marketCap":1530976964},{"date":"2021-06-11","current":-68.131724,"twenty":-223.145513,"median":-23.842011,"eighty":649.10488,"marketCap":1587605441},{"date":"2021-06-18","current":-71.802875,"twenty":-223.145513,"median":-23.92517,"eighty":649.10488,"marketCap":1673150586},{"date":"2021-06-25","current":-75.887676,"twenty":-222.967928,"median":-24.312681,"eighty":648.900759,"marketCap":1768334621},{"date":"2021-07-02","current":-73.526419,"twenty":-222.967928,"median":-24.606789,"eighty":648.900759,"marketCap":1713312626},{"date":"2021-07-09","current":-74.112425,"twenty":-222.967928,"median":-44.751281,"eighty":648.900759,"marketCap":1726967720},{"date":"2021-07-16","current":-62.874913,"twenty":-222.967928,"median":-46.066945,"eighty":648.900759,"marketCap":1465111219},{"date":"2021-07-23","current":-67.631896,"twenty":-222.967928,"median":-46.851785,"eighty":648.900759,"marketCap":1575958449},{"date":"2021-07-30","current":-69.441618,"twenty":-222.967928,"median":-47.492643,"eighty":648.900759,"marketCap":1618128591},{"date":"2021-08-06","current":-116.556997,"twenty":-222.967928,"median":-48.109035,"eighty":648.900759,"marketCap":1564311458},{"date":"2021-08-13","current":-107.938662,"twenty":-222.967928,"median":-49.469834,"eighty":648.900759,"marketCap":1448644782},{"date":"2021-08-20","current":-109.829981,"twenty":-222.967928,"median":-51.159368,"eighty":648.900759,"marketCap":1474028176},{"date":"2021-08-27","current":-105.995219,"twenty":-222.967928,"median":-52.039983,"eighty":648.900759,"marketCap":1422561835},{"date":"2021-09-03","current":-108.212191,"twenty":-222.948196,"median":-53.089223,"eighty":648.898305,"marketCap":1452315813},{"date":"2021-09-10","current":-105.605751,"twenty":-222.948196,"median":-54.352435,"eighty":648.898305,"marketCap":1417334784},{"date":"2021-09-17","current":-109.620267,"twenty":-222.948196,"median":-55.22172,"eighty":648.898305,"marketCap":1471213610},{"date":"2021-09-24","current":-99.883567,"twenty":-222.948196,"median":-55.619529,"eighty":648.898305,"marketCap":1340537353},{"date":"2021-10-01","current":-102.201456,"twenty":-222.948196,"median":-56.577216,"eighty":648.898305,"marketCap":1371645743},{"date":"2021-10-08","current":-97.96826,"twenty":-222.928465,"median":-58.230986,"eighty":648.895851,"marketCap":1314832014},{"date":"2021-10-15","current":-101.354817,"twenty":-222.928465,"median":-59.228611,"eighty":648.895851,"marketCap":1360282997},{"date":"2021-10-22","current":-102.443353,"twenty":-222.928465,"median":-60.207213,"eighty":648.895851,"marketCap":1374892241},{"date":"2021-10-29","current":-106.071807,"twenty":-222.928465,"median":-61.050012,"eighty":648.895851,"marketCap":1423589723},{"date":"2021-11-05","current":-107.281292,"twenty":-222.928465,"median":-61.439537,"eighty":648.895851,"marketCap":1439822217},{"date":"2021-11-12","current":-55.251112,"twenty":-222.928465,"median":-61.46539,"eighty":648.895851,"marketCap":1102977952},{"date":"2021-11-19","current":-46.597813,"twenty":-222.928465,"median":-61.46539,"eighty":648.895851,"marketCap":930232140},{"date":"2021-11-26","current":-47.247826,"twenty":-222.928465,"median":-61.46539,"eighty":648.895851,"marketCap":943208351},{"date":"2021-12-03","current":-38.574214,"twenty":-222.928465,"median":-61.46539,"eighty":648.895851,"marketCap":770057033},{"date":"2021-12-10","current":-38.147643,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":761541394},{"date":"2021-12-17","current":-38.371085,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":766001967},{"date":"2021-12-23","current":-40.341437,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":805336107},{"date":"2021-12-31","current":-38.147643,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":761541394},{"date":"2022-01-07","current":-36.847617,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":735588972},{"date":"2022-01-14","current":-38.960159,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":777761658},{"date":"2022-01-21","current":-36.705426,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":732750426},{"date":"2022-01-28","current":-34.999142,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":698687871},{"date":"2022-02-04","current":-24.987669,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":721493944},{"date":"2022-02-11","current":-26.786556,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":773435015},{"date":"2022-02-18","current":-26.449265,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":763696064},{"date":"2022-02-25","current":-29.765963,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":859462415},{"date":"2022-03-04","current":-30.819998,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":889896636},{"date":"2022-03-11","current":-25.943327,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":749087638},{"date":"2022-03-18","current":-29.147595,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":841607671},{"date":"2022-03-25","current":-29.077326,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":839578723},{"date":"2022-04-01","current":-32.801585,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":947112973},{"date":"2022-04-08","current":-30.637299,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":884621371},{"date":"2022-04-14","current":-30.257846,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":873665051},{"date":"2022-04-22","current":-29.021111,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":837955565},{"date":"2022-04-29","current":-26.280619,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":758826589},{"date":"2022-05-06","current":-19.196392,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":624420233},{"date":"2022-05-13","current":-19.986315,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":650114860},{"date":"2022-05-20","current":-19.572546,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":636655770},{"date":"2022-05-27","current":-20.161854,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":655824777},{"date":"2022-06-03","current":-20.099161,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":653785521},{"date":"2022-06-10","current":-18.55693,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":603619820},{"date":"2022-06-17","current":-17.227853,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":560387590},{"date":"2022-06-24","current":-18.770084,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":610553291},{"date":"2022-07-01","current":-18.268545,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":594239242},{"date":"2022-07-08","current":-18.694853,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":608106183},{"date":"2022-07-15","current":-19.033392,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":619118167},{"date":"2022-07-22","current":-19.998854,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":650522711},{"date":"2022-07-29","current":-19.321776,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":628498745},{"date":"2022-08-05","current":-18.27617,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":674993785},{"date":"2022-08-12","current":-18.375557,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":678664446},{"date":"2022-08-19","current":-16.803903,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":620618538},{"date":"2022-08-26","current":-15.495084,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":572279932},{"date":"2022-09-02","current":-14.530107,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":536640452},{"date":"2022-09-09","current":-15.672551,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":578834319},{"date":"2022-09-16","current":-15.672551,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":578834319},{"date":"2022-09-23","current":-14.341549,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":529676415},{"date":"2022-09-30","current":-15.726213,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":580816217},{"date":"2022-10-07","current":-14.568872,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":538072166},{"date":"2022-10-14","current":-14.70503,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":543100878},{"date":"2022-10-21","current":-15.828331,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":584587751},{"date":"2022-10-28","current":-16.804128,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":620626852},{"date":"2022-11-04","current":-15.356608,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":598078472},{"date":"2022-11-11","current":-15.776012,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":614412548},{"date":"2022-11-18","current":-15.496409,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":603523164},{"date":"2022-11-25","current":-15.270577,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":594727893},{"date":"2022-12-02","current":-14.980221,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":583419686},{"date":"2022-12-09","current":-14.453279,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":562897386},{"date":"2022-12-16","current":-15.603949,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":607711389},{"date":"2022-12-23","current":-14.324231,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":557871516},{"date":"2022-12-30","current":-14.646849,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":570436190},{"date":"2023-01-06","current":-15.410378,"twenty":-221.981345,"median":-61.14502,"eighty":648.893398,"marketCap":600172585},{"date":"2023-01-13","current":-15.055498,"twenty":-220.996594,"median":-60.343621,"eighty":648.893398,"marketCap":586351444},{"date":"2023-01-20","current":-14.732881,"twenty":-218.210257,"median":-59.815039,"eighty":648.893398,"marketCap":573786770},{"date":"2023-01-27","current":-14.388755,"twenty":-216.298622,"median":-58.757875,"eighty":648.893398,"marketCap":560384451},{"date":"2023-02-03","current":-15.829781,"twenty":-213.098642,"median":-57.579104,"eighty":648.893398,"marketCap":616506661},{"date":"2023-02-10","current":-21.828798,"twenty":-209.864261,"median":-56.194141,"eighty":648.893398,"marketCap":826591078},{"date":"2023-02-17","current":-21.828798,"twenty":-206.639894,"median":-55.413615,"eighty":648.893398,"marketCap":826591078},{"date":"2023-02-24","current":-21.828798,"twenty":-204.396855,"median":-55.251112,"eighty":648.893398,"marketCap":826591078},{"date":"2023-03-03","current":-21.928523,"twenty":-200.181145,"median":-54.89758,"eighty":648.893398,"marketCap":830367383},{"date":"2023-03-10","current":-21.69583,"twenty":-195.294526,"median":-53.276878,"eighty":648.893398,"marketCap":821556006},{"date":"2023-03-17","current":-22.020055,"twenty":-191.11887,"median":-52.525462,"eighty":648.893398,"marketCap":833833428},{"date":"2023-03-24","current":-22.109205,"twenty":-188.575425,"median":-51.759312,"eighty":648.893398,"marketCap":837209272},{"date":"2023-03-31","current":-22.131493,"twenty":-184.820339,"median":-51.013718,"eighty":648.890944,"marketCap":838053233},{"date":"2023-04-06","current":-22.164924,"twenty":-177.300152,"median":-49.651896,"eighty":648.893398,"marketCap":839319174},{"date":"2023-04-14","current":-22.24293,"twenty":-171.241947,"median":-48.700677,"eighty":648.895851,"marketCap":842273038},{"date":"2023-04-21","current":-22.265218,"twenty":-159.435956,"median":-47.656498,"eighty":648.895851,"marketCap":843116999},{"date":"2023-04-26","current":-22.276361,"twenty":-150.263532,"median":-47.492643,"eighty":648.895851,"marketCap":843538979}],"updateTime":1772826818027},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSII\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2584295828","title":"This Medical Device Maker Is Seeing High Demand In Cardiovascular, Diabetes Business","url":"https://stock-news.laohu8.com/highlight/detail?id=2584295828","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584295828?lang=en_us&edition=fundamental","pubTime":"2025-11-18 21:58","pubTimestamp":1763474325,"startTime":"0","endTime":"0","summary":"Medtronic reports strong Q2 2026 results with sales of around $9 billion, surpassing estimates. Organic growth at 5.5%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/earnings/25/11/48921968/this-medical-device-maker-is-seeing-high-demand-in-cardiovascular-diabetes-business","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","LU1989764748.USD","LU0211326839.USD","LU1057294990.SGD","LU1571399168.USD","LU1244550494.USD","LU1989771016.USD","MDT","LU1023059063.AUD","LU1983299246.USD","LU1116320901.HKD","LU0072461881.USD","BK4588","LU0211331839.USD","LU0265550359.USD","BK4566","LU0496365809.HKD","LU2023251221.USD","LU2028103732.USD","LU2111349929.HKD","LU2271345857.HKD","LU0432979614.USD","IE00BQXX3C00.GBP","LU0976567544.SGD","LU0162691827.USD","LU2089984988.USD","LU1506573853.SGD","LU0070302665.USD","LU0211326755.USD","LU1989764664.SGD","CSII","IE00BQXX3F31.USD","BK4585","IE00BQXX3D17.EUR","LU0158827781.USD","LU0208291251.USD","LU0265550946.USD","LU1291159041.SGD","LU2468319806.SGD","LU1061106388.HKD","LU1116320737.USD","LU1244550577.SGD","LU0314106906.USD","LU0122379950.USD","IE00BFXG1179.USD","LU0158827948.USD","LU2112291526.USD","LU1244550221.USD","BK4533","LU0320765489.SGD"],"gpt_icon":0},{"id":"2584893534","title":"Acotec Scientific Gains Approval for New Cardiovascular Device","url":"https://stock-news.laohu8.com/highlight/detail?id=2584893534","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584893534?lang=en_us&edition=fundamental","pubTime":"2025-11-18 18:07","pubTimestamp":1763460474,"startTime":"0","endTime":"0","summary":"The latest update is out from Acotec Scientific Holdings Limited ( ($HK:6669) ). Acotec Scientific Holdings Limited announced that it has received ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/acotec-scientific-gains-approval-for-new-cardiovascular-device?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/acotec-scientific-gains-approval-for-new-cardiovascular-device?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CSII","BK4082"],"gpt_icon":0},{"id":"2584986740","title":"Amgen (AMGN) Is Up 5.6% After Repatha Phase 3 Trial Shows Cardiovascular Benefits – Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2584986740","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584986740?lang=en_us&edition=fundamental","pubTime":"2025-11-18 10:24","pubTimestamp":1763432658,"startTime":"0","endTime":"0","summary":"Earlier this month, Amgen announced detailed results from its Phase 3 VESALIUS-CV clinical trial, showing that Repatha® (evolocumab) achieved statistically significant and clinically meaningful reductions in major adverse cardiovascular events in high-risk adults without a prior heart attack or stroke, when added to statins or other LDL-C-lowering treatments.\nThis marks the first large trial to demonstrate a benefit for LDL-C lowering therapy in high-risk adults who have not yet experienced...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/24816-main-header/1756203123218","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/24816-main-header/1756203123218"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/amgen-amgn-is-up-56-after-repatha-phase-3-trial-shows-cardio","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/amgen-amgn-is-up-56-after-repatha-phase-3-trial-shows-cardio","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AMGN","BK4139","LU1983299246.USD","LU0058720904.USD","IE00BJJMRZ35.SGD","IE0002141913.USD","IE00B2B36J28.USD","LU0320765992.SGD","LU1023059063.AUD","BK4599","LU1061106388.HKD","IE00B4R5TH58.HKD","CSII","LU0889565916.HKD","LU1057294990.SGD","LU0289739699.SGD","IE00BFTCPJ56.SGD","IE0009355771.USD","LU2242646821.SGD","LU0122379950.USD","BK4588","BK4533","LU0868494617.USD","BK4581","LU0109394709.USD","LU2468319806.SGD","SG9999001440.SGD","BK4534","BK4082","LU2242652126.USD","LU2089984988.USD","IE00BJT1NW94.SGD","BK4585","LU1571399168.USD","LU2112291526.USD","BK4566"],"gpt_icon":0},{"id":"2583552100","title":"CRISPR Therapeutics (CRSP): Assessing Valuation Following Promising Early CTX310 Cardiovascular Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583552100","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583552100?lang=en_us&edition=fundamental","pubTime":"2025-11-13 13:26","pubTimestamp":1763011586,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics (NasdaqGM:CRSP) drew investor attention after unveiling early data from its Phase 1 CTX310 trial. The results revealed strong, lasting reductions in cardiovascular risk factors and a safety profile that supports ongoing development.\nSee our latest analysis for CRISPR Therapeutics.\nDespite the buzz around CRISPR Therapeutics’ positive CTX310 trial results and solid progress in its gene-editing pipeline, the share price has pulled back sharply this month, down 23.6% in the...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/crispr-therapeutics-crsp-assessing-valuation-following-promi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/crispr-therapeutics-crsp-assessing-valuation-following-promi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CRSP","DCF","BK4082","BK4611","CSII","LU1861559042.SGD","BK4556","LU1861558580.USD","BK4588","BK4585","BK4139"],"gpt_icon":0},{"id":"2582873305","title":"Amgen Says Repatha Significantly Reduces Risk of Cardiovascular Event in Phase 3 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2582873305","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582873305?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:01","pubTimestamp":1762776067,"startTime":"0","endTime":"0","summary":"Amgen  said Saturday that Repatha in combination with cholesterol-lowering treatments showed \"statistically significant and clinically meaningful reductions\" in major adverse cardiovascular events in high-risk adults without a prior heart attack or stroke in a phase 3 clinical trial.The study of more than 12,000 patients with atherosclerosis or diabetes showed that the Repatha addition reduced the risk of a composite of coronary heart disease death, heart attack or ischemic stroke by 25% and the risk of heart attack by 36%.The Repatha addition also \"significantly\" reduced the risk of most secondary endpoints, the company said.Results also showed a reduction in the risk of cardiovascular events in nearly 60% of patients in the trial with diabetes.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0868494617.USD","CSII","LU0289739699.SGD","LU1061106388.HKD","BK4566","LU2112291526.USD","IE00BJJMRZ35.SGD","LU0320765992.SGD","BK4599","LU2089984988.USD","BK4588","BK4533","SG9999001440.SGD","LU1571399168.USD","IE00BFTCPJ56.SGD","LU1983299246.USD","IE00BJT1NW94.SGD","LU0109394709.USD","BK4139","LU0058720904.USD","BK4585","IE00B4R5TH58.HKD","BK4534","BK4082","LU1023059063.AUD","LU0889565916.HKD","LU2468319806.SGD","LU0122379950.USD","IE0009355771.USD","BK4581","LU2242646821.SGD","LU1057294990.SGD","IE00B2B36J28.USD","LU2242652126.USD","IE0002141913.USD","AMGN"],"gpt_icon":0},{"id":"2582289816","title":"New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2582289816","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582289816?lang=en_us&edition=fundamental","pubTime":"2025-11-10 05:15","pubTimestamp":1762722900,"startTime":"0","endTime":"0","summary":"DUBLIN and BRIDGEWATER, N.J., Nov.  09, 2025  (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today highlighted a newpos","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/09/3184162/18362/en/New-REDUCE-IT-Aspirin-Analysis-Presented-at-AHA-Scientific-Sessions-2025-Reinforces-VASCEPA-VAZKEPA-Icosapent-Ethyl-Reduced-Cardiovascular-Events-in-High-Risk-Patients.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","ARR","TG","BK4139","BK4110","BK4153","AMRN","BK4161","IPE","BK4090","BK4082","CSII","CV"],"gpt_icon":1},{"id":"2582486504","title":"Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2582486504","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582486504?lang=en_us&edition=fundamental","pubTime":"2025-11-09 00:30","pubTimestamp":1762619400,"startTime":"0","endTime":"0","summary":"Data support NEK7 as a potential novel and differentiated therapeutic approach to modulate the NLRP3 inflammasome in multiple cardiovascular and cardiometabolic diseases, including pericarditis and at","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/08/3184076/0/en/Monte-Rosa-Therapeutics-Presents-Preclinical-Data-at-AHA-Scientific-Sessions-2025-on-the-Potential-of-MRT-8102-a-NEK7-directed-Molecular-Glue-Degrader-to-Treat-Cardiovascular-and-C.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRT","GLUE","BK4539","CSII","BK4230","BK4139","BK4082"],"gpt_icon":0},{"id":"2581003731","title":"King-Friend Biochemical Pharmaceutical Passes Drug Consistency Evaluation for Cardiovascular Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2581003731","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581003731?lang=en_us&edition=fundamental","pubTime":"2025-11-07 17:50","pubTimestamp":1762509045,"startTime":"0","endTime":"0","summary":"Nanjing King-Friend Biochemical Pharmaceutical  passed China's medical products administrator's generic drug quality and efficacy consistency evaluation for nadroparin calcium injection.The drug is used to prevent and treat thrombosis and related cardiovascular conditions, according to a filing made on Friday with the Shanghai Stock Exchange.Shares of the pharmaceutical company closed 2% higher Friday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0186","BK0046","603707","BK4082","BK0239","CSII"],"gpt_icon":0},{"id":"2581301330","title":"Higher-Dose Of Wegovy Demonstrates Weight Loss And Cardiovascular Benefits","url":"https://stock-news.laohu8.com/highlight/detail?id=2581301330","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581301330?lang=en_us&edition=fundamental","pubTime":"2025-11-07 00:45","pubTimestamp":1762447500,"startTime":"0","endTime":"0","summary":"At the ObesityWeek, Novo Nordisk A/S  presented new findings from the STEP UP phase 3b trial.The Novo Nordisk STEP UP phase 3b trial investigated the efficacy and safety of a higher, 7.2 mg dose of semaglutide compared to the 2.4 mg dose and a placebo for weight management in adults with obesity.It showed that Wegovy helps obese people lose an average of 21% of their body weight.The company on Thursday said Wegovy also enabled the participants to achieve treatment targets linked to a low risk of obesity-related complications.The results applied to both the approved semaglutide 2.4 mg dose and the investigational higher 7.2 mg dose.In the STEP UP sub-analysis, more people with obesity who received Wegovy achieved the target BMI of less than 27, as well as a waist-to-height ratio of less than 0.53.People treated with Wegovy who achieved both treatment targets reached healthy levels for two or more cardiovascular risk factors, including blood pressure, cholesterol, and blood sugar levels.","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/06/Wegovy.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/06/Wegovy.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/25/11/48694189/higher-dose-of-wegovy-demonstrates-weight-loss-and-cardiovascular-benefits","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/11/48694189/higher-dose-of-wegovy-demonstrates-weight-loss-and-cardiovascular-benefits","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["LU1093756168.USD","EMA","BK4585","NVO","BK4081","LU1093756325.SGD","BK4599","IE00BZ1G4Q59.USD","BK4532","CSII","BK4007","LU0154236417.USD","IE00BKVL7J92.USD","BK4588","BK4082"],"gpt_icon":1},{"id":"2578677584","title":"Alnylam’s ZENITH Study: A New Horizon in Cardiovascular Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2578677584","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578677584?lang=en_us&edition=fundamental","pubTime":"2025-10-28 06:57","pubTimestamp":1761605845,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals (($ALNY)) announced an update on their ongoing clinical study. Alnylam Pharmaceuticals is conducting a pivotal Phase 3 clin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alnylams-zenith-study-a-new-horizon-in-cardiovascular-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alnylams-zenith-study-a-new-horizon-in-cardiovascular-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CSII","BK4082"],"gpt_icon":0},{"id":"2578674033","title":"Amgen’s Maridebart Cafraglutide: A New Hope for Cardiovascular Health?","url":"https://stock-news.laohu8.com/highlight/detail?id=2578674033","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578674033?lang=en_us&edition=fundamental","pubTime":"2025-10-28 06:14","pubTimestamp":1761603292,"startTime":"0","endTime":"0","summary":"Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is conducting a Phase 3 clinical study titled A Phase 3 Randomi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/amgens-maridebart-cafraglutide-a-new-hope-for-cardiovascular-health?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/amgens-maridebart-cafraglutide-a-new-hope-for-cardiovascular-health?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0002141913.USD","IE00BJT1NW94.SGD","LU2242646821.SGD","LU2112291526.USD","IE00B2B36J28.USD","LU1571399168.USD","LU1057294990.SGD","SG9999001440.SGD","BK4599","LU0889565916.HKD","LU1023059063.AUD","IE00BJJMRZ35.SGD","BK4581","BK4588","CSII","LU0320765992.SGD","BK4139","IE00B4R5TH58.HKD","LU1061106388.HKD","AMGN","IE0009355771.USD","LU2242652126.USD","LU0289739699.SGD","BK4533","LU0058720904.USD","BK4534","BK4585","LU1983299246.USD","LU0109394709.USD","LU2468319806.SGD","BK4082","LU0122379950.USD","LU2089984988.USD","LU0868494617.USD","IE00BFTCPJ56.SGD","BK4566"],"gpt_icon":0},{"id":"2578622286","title":"NewAmsterdam Pharma’s REMBRANDT Trial: A Potential Game-Changer in Cardiovascular Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2578622286","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578622286?lang=en_us&edition=fundamental","pubTime":"2025-10-28 02:32","pubTimestamp":1761589970,"startTime":"0","endTime":"0","summary":"Newamsterdam Pharma Company N.V. (($NAMS)) announced an update on their ongoing clinical study. NewAmsterdam Pharma Company N.V. (NAMS) is conducti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/newamsterdam-pharmas-rembrandt-trial-a-potential-game-changer-in-cardiovascular-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/newamsterdam-pharmas-rembrandt-trial-a-potential-game-changer-in-cardiovascular-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","CSII","BK4139","NAMS"],"gpt_icon":0},{"id":"2578645275","title":"Amarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit","url":"https://stock-news.laohu8.com/highlight/detail?id=2578645275","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578645275?lang=en_us&edition=fundamental","pubTime":"2025-10-27 20:00","pubTimestamp":1761566400,"startTime":"0","endTime":"0","summary":"DUBLIN and BRIDGEWATER, N.J., Oct.  27, 2025  (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care worldwide, today issued the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/27/3174541/18362/en/Amarin-Issues-Statement-Supporting-FDA-s-Action-to-Revise-Labeling-for-Fenofibrate-Drugs-Reinforcing-a-Lack-of-Cardiovascular-Benefit.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TG","WAC","BK4082","IPE","BK4090","CSII","AMRN","CV","BK4153","BK4139"],"gpt_icon":0},{"id":"2577351142","title":"Autonomix Medical, Inc. Featured in Two Innovation in Interventional Cardiology Podium Presentations at the Transcatheter Cardiovascular Therapeutics® (TCT®) Annual Scientific Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2577351142","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577351142?lang=en_us&edition=fundamental","pubTime":"2025-10-24 21:00","pubTimestamp":1761310800,"startTime":"0","endTime":"0","summary":"THE WOODLANDS, TX, Oct.  24, 2025  (GLOBE NEWSWIRE) -- Autonomix Medical, Inc.(NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted tr","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/24/3172838/0/en/Autonomix-Medical-Inc-Featured-in-Two-Innovation-in-Interventional-Cardiology-Podium-Presentations-at-the-Transcatheter-Cardiovascular-Therapeutics-TCT-Annual-Scientific-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRF","BK4082","CSII","BK4139","AMIX","BK4539","LENZ","BK4007"],"gpt_icon":0},{"id":"2577392177","title":"Semler Scientific’s QuantaFlo HD Study: A Potential Game-Changer in Cardiovascular Diagnostics","url":"https://stock-news.laohu8.com/highlight/detail?id=2577392177","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577392177?lang=en_us&edition=fundamental","pubTime":"2025-10-23 00:30","pubTimestamp":1761150609,"startTime":"0","endTime":"0","summary":"Semler Scientific (($SMLR)) announced an update on their ongoing clinical study. Semler Scientific is currently conducting the QuantaFlo HD Clinica...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/semler-scientifics-quantaflo-hd-study-a-potential-game-changer-in-cardiovascular-diagnostics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/semler-scientifics-quantaflo-hd-study-a-potential-game-changer-in-cardiovascular-diagnostics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0234572021.USD","LU0823434740.USD","LU1551013342.USD","LU2756315318.SGD","LU1162221912.USD","LU1093756168.USD","LU1496350171.SGD","LU0689472784.USD","LU0079474960.USD","LU0820562030.AUD","LU0820561909.HKD","LU0823411888.USD","LU0868494708.USD","BK4585","BK4588","LU0943347566.SGD","LU1929549753.HKD","LU1551013425.SGD","CSII","BK4083","LU2756315664.SGD","LU1035775433.USD","BK4581","LU0354030511.USD","IE00B1XK9C88.USD","LU1674673691.USD","LU1989772923.USD","IE00BZ1G4Q59.USD","LU0942090050.USD","LU1989772840.SGD","BK4566","LU1674673428.USD","BK4534","HD","LU0354030438.USD","SG9999001440.SGD","LU0238689110.USD","IE00BSNM7G36.USD","IE00BWXC8680.SGD","LU1914381329.SGD","BK4504","LU1093756325.SGD","LU1496350502.SGD","BK4567","BK4550","LU0868494617.USD","LU0820561818.USD","LU1069344957.HKD","LU1778281490.HKD","BK4533"],"gpt_icon":0},{"id":"2577363814","title":"Boston Scientific Raises Outlook on Continued Cardiovascular Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2577363814","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577363814?lang=en_us&edition=fundamental","pubTime":"2025-10-22 18:45","pubTimestamp":1761129900,"startTime":"0","endTime":"0","summary":"Boston Scientific recorded higher third-quarter sales and raised its full-year earnings guidance on the back of continued growth in its cardiovascular segment.The medical device company logged net income of $755 million, or 51 cents a share, up from $469 million, or 32 cents a share the year prior.Adjusted earnings were 75 cents a share. Analysts had expected 71 cents, according to FactSet.Sales rose 20% to $5.07 billion, beating Wall Street's forecast of $4.97 billion. Top-line gains were fueled by the company's cardiovascular segment, which saw 22% net sales growth in the quarter.The company increased its full-year adjusted earnings guidance to $3.02 to $3.04 a share from its previous forecast of $2.95 to $2.99 a share. Analysts see full-year adjusted earnings of $2.98.Boston Scientific also guided for fourth-quarter earnings of 77 cents to 79 cents a share. Analysts see 76 cents a share.Earlier this month, the company agreed to acquire the rest of Nalu Medical, a medical technology ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BSX","LU2112291526.USD","LU0345769631.USD","LU0353189763.USD","IE00BJT1NW94.SGD","LU1989771016.USD","SGXZ57979304.SGD","LU2506952170.USD","LU1791710582.SGD","LU2491050154.USD","BK4581","LU0238689110.USD","CSII","LU2491049909.HKD","LU1057294990.SGD","LU0823417653.USD","LU1989772840.SGD","LU0882574055.USD","LU2242649171.HKD","LU2244417387.USD","LU2362541273.HKD","LU0345769128.USD","IE0002141913.USD","LU0528227936.USD","LU1791710400.SGD","LU1989764748.USD","LU1720051108.HKD","SG9999001176.USD","LU2357305700.SGD","IE00BJJMRZ35.SGD","LU0114720955.EUR","LU2506951875.HKD","LU1548497426.USD","LU2506952097.USD","BK4082","LU2362541513.USD","LU1718418525.SGD","LU1989772923.USD","LU1804176565.USD","LU2506951958.HKD","LU0823416689.USD","LU2491050071.SGD","LU1023059063.AUD","LU1366192091.USD","LU2087625088.SGD","LU0187121727.USD","BK4588","IE00BFTCPJ56.SGD","BK4504","LU1989764664.SGD"],"gpt_icon":0},{"id":"2576634550","title":"Could Caristo Collaboration Reveal NewAmsterdam Pharma’s (NAMS) Real Edge in Cardiovascular Innovation?","url":"https://stock-news.laohu8.com/highlight/detail?id=2576634550","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576634550?lang=en_us&edition=fundamental","pubTime":"2025-10-17 22:25","pubTimestamp":1760711122,"startTime":"0","endTime":"0","summary":"Caristo Diagnostics recently announced its selection as the worldwide imaging core lab for NewAmsterdam Pharma’s global REMBRANDT Cardiovascular Imaging Trial, covering coronary plaque and inflammation measurement across 50 trial sites in 7 countries.\nThis collaboration enables NewAmsterdam to incorporate advanced imaging analytics and standardized data quality in a large-scale trial evaluating obicetrapib and ezetimibe for coronary plaque reduction.\nWe'll explore how the integration of...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nams/newamsterdam-pharma/news/could-caristo-collaboration-reveal-newamsterdam-pharmas-nams","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nams/newamsterdam-pharma/news/could-caristo-collaboration-reveal-newamsterdam-pharmas-nams","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4082","CSII","NAMS","BK4139"],"gpt_icon":0},{"id":"2575257215","title":"HLS Therapeutics and Amarin Highlight Cardiovascular Advances at Canadian Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2575257215","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575257215?lang=en_us&edition=fundamental","pubTime":"2025-10-14 21:14","pubTimestamp":1760447664,"startTime":"0","endTime":"0","summary":"An announcement from HLS Therapeutics Inc ( ($TSE:HLS) ) is now available. HLS Therapeutics Inc., in collaboration with Amarin Corporation, announc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/hls-therapeutics-and-amarin-highlight-cardiovascular-advances-at-canadian-congress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/hls-therapeutics-and-amarin-highlight-cardiovascular-advances-at-canadian-congress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LENZ","BK4539","CSII","BK4082","BK4139"],"gpt_icon":0},{"id":"2575579263","title":"Shandong Xinhua Pharmaceutical Gets Regulatory Nod for Cardiovascular Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2575579263","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575579263?lang=en_us&edition=fundamental","pubTime":"2025-10-14 14:24","pubTimestamp":1760423055,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical  obtained drug registration from China's medical products regulator for its bisoprolol fumarate tablets.The drug is indicated for treating hypertension, angina and chronic heart failure, according to Tuesday filing with the Shenzhen bourse.Shres of the pharmaceutical company rose 2% in recent trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0164","CSII","BK4082","000756","BK0239"],"gpt_icon":0},{"id":"2573295673","title":"Strategic Shift Towards Cardiovascular Platform Positions Rocket Pharmaceuticals for Future Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2573295673","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573295673?lang=en_us&edition=fundamental","pubTime":"2025-10-06 17:25","pubTimestamp":1759742734,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst on October 3. Analyst Jason Zemansky from Bank of Ame...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/strategic-shift-towards-cardiovascular-platform-positions-rocket-pharmaceuticals-for-future-growth-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/strategic-shift-towards-cardiovascular-platform-positions-rocket-pharmaceuticals-for-future-growth-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","BK4585","LABU","CSII","BK4588","XBI","XLV","BK4082"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":46,"code":"91000000","status":"200"}]}}